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ISOPROTERENOL, a potent beta-adrenergic stimulator, has been widely used for the treatment of cardiac failure, cardiogenic shock, or low output syndrome following open heart surgery. [1] [2] [3] Although infusion of isoproterenol improves myocardial performance, occurrence of adverse side effects such as tachycardia, ventricular arrhythmia, and reduced perfusion pressure, often necessitates the discontinuation of this drug. Furthermore, isoproterenol has been shown experimentally to intensify myocardial ischemia and to extend infarct size after coronary narrowing or occlusion resulting in acute myocardial failure. 4 An agent with inotropic effect as potent as isoproterenol but without significant effects on vasomotor tone, heart rate, or rhythm would be desirable for the treatment of myocar-from 33.4 ± 2.3 to 37.1 ± 2.5 mm Hg with 8 Ag/kg/min, while other pressures were unchanged. Mean left atrial pressure fell significantly from 15.9 ± 0.6 to 14.8 ± 0.7 mm Hg. Stroke volume index, stroke work index, and left ventricular work also increased. Premature ventricular beats were observed in only one patient during dobutamine infusion, but no other side effect was observed.
We conclude that dobutamine is a potent inotropic agent which increases cardiac output without causing significant tachycardia or arrhythmias, and is useful for the treatment of patients following open heart surgery. dial pump failure. Recently, Tuttle and Millis synthesized a new beta-adrenergic stimulator. 6 This new beta-adrenergic stimulator, dobutamine, which is synthesized by modifying the side-chain of dopamine, is reported to have a strong inotropic action with a weak chronotropic action and little effect on peripheral vessels. [7] [8] [9] [10] [11] [12] [13] [14] In this study, we examined the acute hemodynamic effects of dobutamine on patients following open heart surgery and compared the hemodynamic responses with isoproterenol infusion.
Method and Materials
The study group (table I) 
consisted of 22 patients hospitalized at the Tokyo Medical and Dental University
Hospital for open heart surgery. Their ages ranged from 19 to 54 years with a mean of 32.5 years. The surgical procedure for aortic valve replacement with the Starr-Edwards ball prosthesis was performed during either coronary perfusion or a period of anoxic arrest. For other surgical procedures which included mitral valve replacement with the Starr-Edwards disc prosthesis, an anoxic arrest was used. The cardiopulmonary bypass technique utilized hemodilution, the Temptrol Q-100 disposable bubble oxygenator, and perfusion rates of 3.0 L/min/m2 at normothermia.
At operation, 19 gauge Teflon catheters (30 cm in length) were placed in the main trunk of the pulmonary artery and the left atrium. They were connected through the operative wound to metal three-cockplates outside of the thorax. In order to keep the catheters patent postoperatively, one arm of the three-way cock was connected to a continuous microinfusion pump. The remaining arm was connected to an electric manometer. A 19 gauge polyethylene catheter (70 cm in length) was inserted into the left radial artery and passed to the aortic arch.
Central aortic pressure was measured through the catheter, which was used also as the cuvette circuit for dyedilution method to determine the cardiac output. Pulmonary arterial pressure, left atrial pressure, and aortic pressure were simultaneously obtained from the Statham P-23Db pressure transducers using the midchest as the zero reference point and recorded at various paper speeds on multichannel recorder. Mean values of these pressures were also obtained using an electronic integrating circuit. Cardiac output was determined by duplicated dye-dilution technique. After sequential injections of indocyanine green (5 mg) into the main trunk of the pulmonary artery and the left atrium, arterial blood was sampled by continuous withdrawal pump at a speed of 34.5 ml/min. Dye-dilution curves were recorded and the cardiac output was computed by an -Erma Blood Flow Computer (Erma Optical Company). The arithmetic mean of cardiac output was derived from the average of the two curves which were obtained from the injections into the trunk of the pulmonary artery and the left atrium. Left ven-tricular stroke work index (LVSWI) in g-m/beat/m' and systemic vascular resistance (SVR) in units were calculated as follows: LVSWI = SVI X (MAP -MLAP)X 13.6 1000 SVR = MAP CO Where SVI = stroke volume index (ml/beat/m2), MAP = mean aortic pressure (mm Hg) and CO = cardiac output (L/min).
Studies were carried out within six hours following open heart surgery. Dobutamine was infused with a Harvard infusion pump and its dose was increased stepwise from 2 to 4, 6, and 8 Atg/kg/min at a 15 min interval. Various hemodynamic parameters mentioned above were determined before the start of infusion, during the infusion at a rate of 2, 4, 6 and 8 Mg/kg/min, and at 5 and 10 minutes after stopping the infusion. In three of the 22 patients studied, the response to dobutamine was tested in a similar manner 12 to 24 hours after the original test. Thus, the final statistical analysis of the effects of dobutamine on hemodynamics was made with a total number of 25.
In nine out of the 22 patients, isoproterenol was infused with a Harvard infusion pump at 30 min after the dobutamine study and its dose was increased from 0.005 to 0.01 and 0.02 ,ug/kg/min at 15 min intervals. Hemodynamic results obtained with dobutamine and isoproterenol in the same nine patients were compared with each other.
All patients received blood transfusion to maintain left atrial pressure above 12 mm Hg and 21 patients had an uneventful recovery and did not require pharmacological support therapeutically during the postoperative period. Statistical analysis utilized the Student's t-test on a paired or unpaired basis as appropriate. A P value of less than 0.05 was considered to indicate a significant difference between compared group of data. Table 2 shows changes in various hemodynamic parameters obtained from dobutamine infusion. With infusion of dobutamine, systolic aortic pressure showed a significant and constant increase by 17.1 mm Hg (13.6%) from an average of 126.0 ± 3.8 to 144.6 ±: 6.0 mm Hg, but on discontinuation of infusion, it immediately decreased to a level lower than the control value by 2 mm Hg ( fig. 1 ). No significant change was observed in diastolic aortic pressure but mean aortic pressure showed a significant increase by 4.4 mm Hg (4.8%) from an average of 91.8 ± 2.7 to 96.2 ± 3.2 mm Hg. Pulmonary arterial pressure showed changes similar to aortic pressure. Systolic pulmonary arterial pressure showed a significant increase by 3.7 mm Hg (11.1%) from an average of 33.4 ± 2.3 to 37.1 ± 2.5 mm Hg with dobutamine but it showed a significantly lower value than the control after its termination. No significant change was observed either in diastolic or mean pulmonary arterial pressure with dobutamine infusion. However, mean pulmonary arterial pressure showed a significant decrease after discontinuation of dobutamine. Mean left atrial pressure showed a slight but significant decrease from an average of 15.9 ± 0.6 to 14.8 + 0.7 mm Hg (7.2%). After discontinuation of dobutamine, mean left atrial pressure remained at the decreased level. Cardiac index showed a significant stepwise increase with graded doses of dobutamine ( fig. 2 ). The increase in cardiac index with each increase of dobutamine dose was 13.4, 22.4, 31.4, and 37.7%, respectively, and the overall increase was from an average of 2.54 + 0.13 to 3.50 + 0.22 L/min/m2. With cessation of dobutamine, cardiac index showed a decrease and was at the control level after 10 min. Heart rate increased significantly from an average of 87.6 ± 2.9 to 108.9 ± 3.2 beats/min (24.3%) but returned to the control value 10 min after the stop of infusion.
Results
The only arrhythmia that developed in these cases during dobutamine infusion was premature ventricular beats observed in a patient (E.K.). In a 39-year-old female patient (A.S.) with atrial septal defect, multiple premature ventricular beats were observed before infusion of dobutamine, but they disappeared during dobutamine infusion. With discontinuation of dobutamine, the arrhythmia reappeared.
Left ventricular stroke work index showed a significant increase of 11.8%, from an average of 32.1 ± 2.9 to 35.9 ± 3.2 g-m/beats/m2, immediately after the onset of dobutamine infusion, and reached a plateau and returned to the control level upon the cessation of dobutamine. Calculated systemic vascular resistance showed a significant decrease, from an average of 24.7 + 1.3 to 19.3 ± 1.2 units (21.8%), but returned to the control value after dobutamine infusion. The decrease in systemic vascular resistance was due to marked increase of cardiac output by dobutamine but not to a direct vasoactive effect of the drug. During hemodynamic studies, an interesting finding was observed in a 21-year-old patient (H.S.). His urinary output was between 40 and 50 ml/hour before infusion of dobutamine but during dobutamine infusion urine volume was markedly increased to 450 ml/hour and after the infusion urine volume returned to 42 ml/hour.
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NS
A representative case (Y.O.) is presented below ( fig. 4 ). Aortic valve replacement by the Starr-Edwards ball prosthesis was performed for aortic insufficiency. Immediately postop, the patient was in a stable condition and aortic pressure was 123/71 (90) mm Hg; pulmonary arterial pressure, 31/16 (23) mm Hg; mean left atrial pressure, 15.5 mm Hg, and cardiac index 1.92 L/min/m2. Fourteen hours after surgery, aortic pressure fell to 90/65 (74) mm Hg, cardiac index decreased to 1.06 L/min/m2, and pulmonary arterial pressure and mean left atrial pressure increased. A diagnosis of severe left ventricular failure was made and the infusion of dobutamine at a rate of 6 Ag/kg/min was started. After aortic pressure had been elevated to a safe level, the infusion of phenoxybenzamine at a dose of I mg/kg was added for the purpose of reducing the afterload of the left ventricle. Subsequently cardiac index increased to over 2.0 L/min/m2 and systolic aortic pressure stabilized at 120 mm Hg. The infusion of dobutamine was stopped at 8 hours after initiation, but there was no change in hemodynamics and the patient remained in a satisfactory condition. Sufficient urinary output was also maintained.
Discussion
With the administration of isoproterenol, tachycardia or arrhythmia often develops and necessitates the cessation of infusion before a sufficient increase in cardiac output can be obtained. Myocardial oxygen consumption (MVO2) increases markedly as both myocardial contractile force and heart rate increase with isoproterenol, thus shifting the myocardial metabolism to anaerobic. "5 In an attempt to develop a new beta-adrenergic stimulator without these adverse effects on cardiac rhythm or myocardial metabolism, dobutamine has been synthesized by modifying the side-chain of dopamine.6 It has been reported that dobutamine increases myocardial contractile force selectively. 8 12 In the present study, dobutamine increased systolic and mean aortic pressure and systolic pulmonary arterial pressure significantly but diastolic aortic pressure and diastolic pulmonary arterial pressure remained unaltered. These changes demonstrate that dobutamine produced relatively little change in peripheral vascular resistance at doses less than 8 ,Ag/kg/min. Dobutamine has been shown to possess both vasoconstricting and vasodilating effects on peripheral vessels."6' 17 At low doses, a mild peripheral alpha-adrenergic action predominates, while with higher doses, beta-adrenergic effect is predominant. Holloway et al. observed this biphasic response clinically with dobutamine, with 10 gg/kg/min being the cut-off point,'3 and Robie et al. reported that as the dose of dobutamine was increased to higher than 16 gg/kg/min peripheral vasodilation became predominant and aortic pressure and total peripheral resistance began to lower.", Since dobutamine does not lower aortic pressure, it is expected that the inflow pressure of the coronary arteries is not lowered, thus acting favorably on coronary perfusion. This advantage makes an interesting contrast to isoproterenol which reduces diastolic aortic pressure because of its potent vasodilating action on peripheral vessels.'8 Tuttle et al. reported that in experimental dogs P02 in coronary sinus increased by 35% after infusion of dobutamine, but decreased by 11% after isoproterenol.7 They considered that dobutamine increased myocardial oxygen supply more significantly than myocardial oxygen consumption. The fact obtained from our study that the diastolic aortic pressure was unchanged during dobutamine infusion may also have been responsible for the finding by Tuttle et al. 7 Vatner et al."' reported that in the presence of experimental moderate global ischemia, dobutamine is not as deleterious as isoproterenol. In their experiment, left ventricular function was maintained during dobutamine infusion but acute depression of cardiac function occurred when isoproterenol was substituted for dobutamine.
In the present study, mean left atrial pressure showed a significant, gradual decrease after the start of dobutamine infusion because of the improvement of left ventricular function. These changes in pressure were very similar to those reported by Jewitt patients of whom 17 patients had impaired left ventricular performance. Dobutamine augmented cardiac index by 48% (7.5 ,g/kg/min) in patients with normal left ventricular function and 82% (10.7 Ag/kg/min) in patients with depressed left ventricular function. Discrepancies of the degree of increase in cardiac index is thought to be related to the differences in myocardial contractility reserve before the administration of dobutamine. This is supported by the fact Premature ventricular beats were observed in one patient during dobutamine infusion. This patient, who developed arrhythmia (premature ventricular beat) with dobutamine, developed it during isoproterenol administration as well. Some patients who developed arrhythmia with isoproterenol did not develop any with dobutamine. Thus, the occurrence of premature ventricular contraction is definitely less frequent with dobutamine than with isoproterenol. This is the most useful feature of dobutamine in the postoperative management of patients after open heart surgery. When the hemodynamic responses with dobutamine and isoproterenol were compared in the same nine patients, no significant differences were observed, but dobutamine had less effect on heart rate. For comparable effect on cardiac index, 8 ,ug/ kg/min of dobutamine was equivalent to 0.01 ,ug/kg/ min of isoproterenol. A dose of dobutamine of 4-10 gg/kg/ min was sufficient to improve cardiac performance without any undesirable side effects. Beregovich et al.'0 also found that 5-10 Ag/kg/min was preferable for clinical use. Since the increase in cardiac index was lower in acquired heart disease than in congenital disease, further increase in the dose in acquired heart diseases seemed feasible.
We observed a marked increase in urinary output in one patient. The mechanism of this phenomenon is unknown because the hemodynamic response of this patient did not differ from others. But previous investigators reported that the renal vascular bed showed the least response to dobutamine infusion. '7 20 In conclusion, dobutamine, a new beta-stimulator, shows considerable promise therapeutically. This agent is useful for the treatment of patients following open heart surgery. Undesirable side effects such as tachycardia, arrhythmias, hypotension, and peripheral vasoconstriction do not occur. Moreover, with dobutamine a comparable effect on cardiac index could be attained with less change in heart rate than that caused by isoproterenol, and 8 ,ug/kg/min of dobutamine had an inotropic effect comparable to that of 0.01 ,ug/kg/min of isoproterenol.
Among the patients whose mean blood pressure fell 10 mm Hg or more, peripheral vascular resistance fell significantly (P < 0.025), and the change in plasma volume was not statistically significant. Among the patients whose mean blood pressure changed less than 10 mm Hg with therapy, there was no significant change in peripheral vascular resistance and plasma volume increased significantly (P < 0.025). Prazosin hydrochloride appears to be an effective antihypertensive agent which acts by peripheral vasodilatation. It may cause fluid retention. The drug does not appear to affect renal function or renin secretion. that its antihypertensive action is associated with peripheral vasodilation. The present study was designed to evaluate some physiologic parameters of importance in the therapy of moderate essential hypertension with prazosin HCI.
Methods
Fourteen patients with essential hypertension were studied on an outpatient basis. Criteria for participation in the study included sustained diastolic blood pressure between 90 and 130 mm Hg in patients who had received no antihypertensive therapy in the last four weeks. Diabetes, coronary heart disease, cerebrovascular disease or renal insufficiency were criteria for exclusion from the study. Renal and renovascular causes of hypertension were ruled out with triple isotope renal studies using 197Hg chlormerodrin, "mTc pertechnetate and "'1I orthoiodohippuratell and by rapid sequence intravenous urography. Pheochromocytoma was excluded with urinary VMA. All patients were offered par-
